Konstanze Hurth

731 total citations
19 papers, 423 citations indexed

About

Konstanze Hurth is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Konstanze Hurth has authored 19 papers receiving a total of 423 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 9 papers in Oncology and 8 papers in Epidemiology. Recurrent topics in Konstanze Hurth's work include Neuroendocrine Tumor Research Advances (8 papers), Receptor Mechanisms and Signaling (5 papers) and HER2/EGFR in Cancer Research (5 papers). Konstanze Hurth is often cited by papers focused on Neuroendocrine Tumor Research Advances (8 papers), Receptor Mechanisms and Signaling (5 papers) and HER2/EGFR in Cancer Research (5 papers). Konstanze Hurth collaborates with scholars based in Switzerland and Australia. Konstanze Hurth's co-authors include Daniël Hoyer, Caroline Nunn, Thomas Troxler, Daniel Langenegger, Philipp Floersheim, René Hemmig, Christian Ostermeier, Doncho P. Uzunov, Wolfgang Jahnke and Jason Hannon and has published in prestigious journals such as Angewandte Chemie International Edition, Journal of Medicinal Chemistry and British Journal of Pharmacology.

In The Last Decade

Konstanze Hurth

18 papers receiving 414 citations

Peers

Konstanze Hurth

EPIDE

CTM

ONCOL

П.В. Ершов Russia

James J. Knittel United States

Chrysoula Vraka Austria

Daniel Elbaum United States

Gamini Chandrasena United States

Niall M. Hamilton United Kingdom

Jennifer L. Olkowski United States

Haibei Hu United States

Susan J. Bergstrand United States

Lisa Schindler Germany

П.В. Ершов Russia

Konstanze Hurth

229 ×0.9

23 ×0.3

EPIDE

58 ×0.7

46 ×0.7

CTM

49 ×0.8

ONCOL

Citations per year, relative to Konstanze Hurth Konstanze Hurth (= 1×) peers П.В. Ершов

Countries citing papers authored by Konstanze Hurth

Since Specialization

Citations

This map shows the geographic impact of Konstanze Hurth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Konstanze Hurth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Konstanze Hurth more than expected).

Fields of papers citing papers by Konstanze Hurth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Konstanze Hurth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Konstanze Hurth. The network helps show where Konstanze Hurth may publish in the future.

Co-authorship network of co-authors of Konstanze Hurth

This figure shows the co-authorship network connecting the top 25 collaborators of Konstanze Hurth. A scholar is included among the top collaborators of Konstanze Hurth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Konstanze Hurth. Konstanze Hurth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Martin, Benjamin, et al.. (2025). A Mild Rhodium‐Catalyzed Asymmetric 1,4‐Conjugate Addition of Organoboranes to α‐Substituted Heterocyclic Acrylates for Use in Pharmaceutical Products. Helvetica Chimica Acta. 108(10).

Rueeger, Heinrich, Rainer Machauer, Siem J. Veenstra, et al.. (2021). Synthesis of the Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor NB-360. Journal of Medicinal Chemistry. 64(8). 4677–4696. 11 indexed citations

Machauer, Rainer, Konstanze Hurth, Siem J. Veenstra, et al.. (2021). Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer’s Disease. Journal of Medicinal Chemistry. 64(20). 15262–15279. 25 indexed citations

Veenstra, Siem J., Heinrich Rueeger, Philipp Holzer, et al.. (2018). Discovery of amino-1,4-oxazines as potent BACE-1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 28(12). 2195–2200. 10 indexed citations

Hurth, Konstanze, et al.. (2015). Regioselective nitration of 3-fluoro-2-substituted benzoic acids. Tetrahedron Letters. 56(22). 2860–2862. 3 indexed citations

Feuerbach, Dominik, Nicole Pezous, H. Weiss, et al.. (2014). AQW051, a novel, potent and selectiveα7 nicotinicAChreceptor partial agonist: pharmacological characterization and phaseIevaluation. British Journal of Pharmacology. 172(5). 1292–1304. 27 indexed citations

Troxler, Thomas, Konstanze Hurth, Philippe Schoeffter, et al.. (2010). Decahydroisoquinoline derivatives as novel non-peptidic, potent and subtype-selective somatostatin sst3 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 20(5). 1728–1734. 10 indexed citations

Hintermann, Samuel, Konstanze Hurth, Joachim Nozulak, et al.. (2010). Exploring subtype selectivity and metabolic stability of a novel series of ligands for the benzodiazepine binding site of the GABAA receptor. Bioorganic & Medicinal Chemistry Letters. 21(5). 1523–1526. 5 indexed citations

Troxler, Thomas, Konstanze Hurth, Henri Mattes, et al.. (2009). Discovery of novel non-peptidic β-alanine piperazine amide derivatives and their optimization to achiral, easily accessible, potent and selective somatostatin sst1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 19(5). 1305–1309. 11 indexed citations

10.

Enz, Albert, Dominik Feuerbach, Mathias Frederiksen, et al.. (2009). Gamma-lactams—A novel scaffold for highly potent and selective α7 nicotinic acetylcholine receptor agonists. Bioorganic & Medicinal Chemistry Letters. 19(5). 1287–1291. 31 indexed citations

11.

Troxler, Thomas, Daniël Hoyer, Daniel Langenegger, et al.. (2007). Identification and SAR of potent and selective non-peptide obeline somatostatin sst1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 17(14). 3983–3987. 9 indexed citations

12.

Hurth, Konstanze, Albert Enz, Philipp Floersheim, et al.. (2007). SAR of the arylpiperazine moiety of obeline somatostatin sst1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 17(14). 3988–3991. 8 indexed citations

13.

Troxler, Thomas, Albert Enz, Daniël Hoyer, et al.. (2007). Ergoline derivatives as highly potent and selective antagonists at the somatostatin sst1 receptor. Bioorganic & Medicinal Chemistry Letters. 18(3). 979–982. 7 indexed citations

14.

Hoyer, Daniël, Caroline Nunn, Jason Hannon, et al.. (2004). SRA880, in vitro characterization of the first non-peptide somatostatin sst1 receptor antagonist. Neuroscience Letters. 361(1-3). 132–135. 28 indexed citations

15.

Nunn, Caroline, Daniel Langenegger, Konstanze Hurth, et al.. (2003). Agonist properties of putative small-molecule somatostatin sst2 receptor-selective antagonists. European Journal of Pharmacology. 465(3). 211–218. 13 indexed citations

16.

Nunn, Caroline, Magnus Rueping, Daniel Langenegger, et al.. (2003). β2/β3-di- and α/β3-tetrapeptide derivatives as potent agonists at somatostatin sst4 receptors. Naunyn-Schmiedeberg s Archives of Pharmacology. 367(2). 95–103. 41 indexed citations

17.

Hannon, Jason, Caroline Nunn, Barbara Stolz, et al.. (2002). Drug Design at Peptide Receptors. Journal of Molecular Neuroscience. 18(1-2). 15–28. 91 indexed citations

18.

Jahnke, Wolfgang, Philipp Floersheim, Christian Ostermeier, et al.. (2002). NMR Reporter Screening for the Detection of High-Affinity Ligands. Angewandte Chemie International Edition. 41(18). 3420–3423. 80 indexed citations

19.

Jahnke, Wolfgang, Philipp Floersheim, Christian Ostermeier, et al.. (2002). . Angewandte Chemie. 114(18). 3570–3573. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact